GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Goodwill-to-Asset

Algernon Pharmaceuticals (XCNQ:AGN) Goodwill-to-Asset : 0.00 (As of Nov. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Algernon Pharmaceuticals's Goodwill for the quarter that ended in Nov. 2024 was C$0.00 Mil. Algernon Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 was C$3.66 Mil.


Algernon Pharmaceuticals Goodwill-to-Asset Historical Data

The historical data trend for Algernon Pharmaceuticals's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Goodwill-to-Asset Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Algernon Pharmaceuticals Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Algernon Pharmaceuticals's Goodwill-to-Asset

For the Biotechnology subindustry, Algernon Pharmaceuticals's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Goodwill-to-Asset falls into.


;
;

Algernon Pharmaceuticals Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Algernon Pharmaceuticals's Goodwill to Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as

Goodwill to Asset (A: Aug. 2024 )=Goodwill/Total Assets
=0/3.944
=

Algernon Pharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Nov. 2024 is calculated as

Goodwill to Asset (Q: Nov. 2024 )=Goodwill/Total Assets
=0/3.655
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Algernon Pharmaceuticals Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Executives
Christopher Moreau Director, Senior Officer
Christopher Scott Bryan Senior Officer
James Kinley Senior Officer
Harry J.f. Bloomfield Director
Rajpaul Attariwala Director
Mark Williams Director
Howard Gutman Director
Michael Sadhra Senior Officer
Kulwant Malhi 10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines